These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30026838)

  • 21. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target.
    Chen DT; Pan JH; Chen YH; Xing W; Yan Y; Yuan YF; Zeng WA
    Br J Anaesth; 2019 Jun; 122(6):e157-e167. PubMed ID: 30915986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.
    Mo SJ; Hou X; Hao XY; Cai JP; Liu X; Chen W; Chen D; Yin XY
    Cancer Commun (Lond); 2018 Apr; 38(1):9. PubMed ID: 29764501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
    Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
    Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model.
    Zalles M; Smith N; Saunders D; Saran T; Thomas L; Gulej R; Lerner M; Fung KM; Chung J; Hwang K; Jin J; Battiste J; Towner RA
    Transl Oncol; 2020 Mar; 13(3):100737. PubMed ID: 32208341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cancer-associated fibroblasts up-regulate CCL2, CCL26, IL6 and LOXL2 genes related to promotion of cancer progression in hepatocellular carcinoma cells.
    Lin ZY; Chuang YH; Chuang WL
    Biomed Pharmacother; 2012 Oct; 66(7):525-9. PubMed ID: 22739041
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
    Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
    J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ADGRL4/ELTD1 Silencing in Endothelial Cells Induces ACLY and SLC25A1 and Alters the Cellular Metabolic Profile.
    Favara DM; Zois CE; Haider S; Pires E; Sheldon H; McCullagh J; Banham AH; Harris AL
    Metabolites; 2019 Nov; 9(12):. PubMed ID: 31775252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.
    Ziegler J; Zalles M; Smith N; Saunders D; Lerner M; Fung KM; Patel M; Wren JD; Lupu F; Battiste J; Towner RA
    Am J Nucl Med Mol Imaging; 2019; 9(1):93-109. PubMed ID: 30911439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
    Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-663a inhibits tumor growth and invasion by regulating TGF-β1 in hepatocellular carcinoma.
    Zhang C; Chen B; Jiao A; Li F; Sun N; Zhang G; Zhang J
    BMC Cancer; 2018 Nov; 18(1):1179. PubMed ID: 30486878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
    Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
    Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
    Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
    J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The suppressor of cytokine signaling 2 (SOCS2) inhibits tumor metastasis in hepatocellular carcinoma.
    Cui M; Sun J; Hou J; Fang T; Wang X; Ge C; Zhao F; Chen T; Xie H; Cui Y; Yao M; Li J; Li H
    Tumour Biol; 2016 Oct; 37(10):13521-13531. PubMed ID: 27465557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
    Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinoma.
    He F; Li J; Xu J; Zhang S; Xu Y; Zhao W; Yin Z; Wang X
    J Exp Clin Cancer Res; 2015 May; 34(1):47. PubMed ID: 25975202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A20 suppresses hepatocellular carcinoma proliferation and metastasis through inhibition of Twist1 expression.
    Chen H; Hu L; Luo Z; Zhang J; Zhang C; Qiu B; Dong L; Tan Y; Ding J; Tang S; Shen F; Li Z; Wang H
    Mol Cancer; 2015 Nov; 14():186. PubMed ID: 26538215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
    Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
    Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. TCF12 promotes the tumorigenesis and metastasis of hepatocellular carcinoma via upregulation of CXCR4 expression.
    Yang J; Zhang L; Jiang Z; Ge C; Zhao F; Jiang J; Tian H; Chen T; Xie H; Cui Y; Yao M; Li H; Li J
    Theranostics; 2019; 9(20):5810-5827. PubMed ID: 31534521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uridine-cytidine kinase 2 upregulation predicts poor prognosis of hepatocellular carcinoma and is associated with cancer aggressiveness.
    Huang S; Li J; Tam NL; Sun C; Hou Y; Hughes B; Wang Z; Zhou Q; He X; Wu L
    Mol Carcinog; 2019 Apr; 58(4):603-615. PubMed ID: 30556610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Golgi phosphoprotein 3 (GOLPH3) promotes hepatocellular carcinoma progression by activating mTOR signaling pathway.
    Liu H; Wang X; Feng B; Tang L; Li W; Zheng X; Liu Y; Peng Y; Zheng G; He Q
    BMC Cancer; 2018 Jun; 18(1):661. PubMed ID: 29914442
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.